Newswise — SEPTEMBER 19, 2019, New York— Ludwig Cancer Research welcomes Alexandra Johnson to the Board of Directors of the Ludwig Institute for Cancer Research.
Johnson has since 2017 been a partner at the Swiss law firm Bär & Karrer. She has over the course of her distinguished career served as counsel in arbitration proceedings on matters ranging from international joint venture agreements to mergers and acquisitions and even sport-related disputes. In addition to her counsel work, she also frequently sits as an arbitrator.
As an attorney, she advises clients on Swiss contract law and litigates before the Swiss cantonal courts, as well as before the Swiss Federal Supreme Court. A frequent speaker who has published extensively on her field of law, Johnson serves as co-chair of the Geneva Local Group of the Swiss Arbitration Association, is a member of the Academic Counsel of the Swiss Arbitration Academy, board member of ArbitralWomen and a recipient of the Distinguished Service Award of the American Arbitration Association.
Johnson earned her Law degree from the University of Neuchatel and an LL.M degree from Harvard Law School, which she attended as a Fulbright Scholar. She was admitted to the Bar in Switzerland in 1999 and to the New York Bar in 2001 (not practicing).
“With 17 years of experience in international arbitration law, Johnson brings to Ludwig professional skills and legal insight of high value to an international organization conducting scientific research in partnership with institutions around the world,” said John L. Notter, Board Chair, Ludwig Institute for Cancer Research. “We look forward to having her on the Board and are confident her expertise and guidance will be of great benefit to Ludwig’s mission to advance the prevention, diagnosis and treatment of cancer.”
About Ludwig Cancer Research
Ludwig Cancer Research is an international collaborative network of acclaimed scientists that has pioneered cancer research and landmark discovery for 48 years. Ludwig combines basic science with the ability to translate its discoveries and conduct clinical trials to accelerate the development of new cancer diagnostics and therapies. Since 1971, Ludwig has invested $2.7 billion in life-changing science through the not-for-profit Ludwig Institute for Cancer Research and the six U.S.-based Ludwig Centers. To learn more, visit www.ludwigcancerresearch.org.
For further information please contact Rachel Reinhardt, [email protected] or +1-212-450-1582.